doi.org/10.36721/PJPS.2022.35.5.REG.1391-1398.1

In-silico, synthesis, structure elucidation and anticancer activity study of 2-(3,4-dichlorophenyl)-4*H*-benzo[d][1,3]oxazin-4-one

Dini Kesuma[1], Tegar Achsendo Yuniarta[1], Galih Satrio Putra[1,2]*, Sumari Sumari[2] Melanny Ika Sulistyowaty[3] and Farida Anwari[4]

[1]Pharmaceutical Chemistry Department, Faculty of Pharmacy University of Surabaya, Surabaya, Indonesia
[2]Department of Chemistry, Faculty of Mathematics and Natural Sciences, State University of Malang, Malang, Indonesia
[3]Pharmaceutical Sciences Department, Faculty of Pharmacy Airlangga University, Surabaya, Indonesia
[4]Medical Laboratory Science, University of Anwar Medika, Sidoarjo, Indonesia

Abstract: The research aims to synthesize 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one and evaluate its anticancer activity against MCF-7. This compound was selected based on *in-silico* study conducted against several dihalophenylbenzoxazinone analogues using molecular docking towards Methionyl-tRNA synthetase. Synthesis of target compound was carried out using anthranilic acid and 3,4-dichlorobenzoyl chloride. The resulting compound was characterized using various spectroscopic analysis: 1D and 2D NMR, infrared and MS. *In-silico* studies was performed by MVD. Several designed compounds were docked into the active site on Methionyl-tRNA Synthetase (1PG2). Anticancer activity was evaluated by MTT Assay against MCF-7. 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one has been successfully synthesized with decent amount of yield 88 %. Its spectroscopic analysis 1D and 2D NMR, MS, FTIR has proven the chemical structure of compound. *In-silico* studies toward the enzyme showed docking score of -76.04 Kcal/mol, higher than its native ligand (-93.50 Kcal/mol). Meanwhile, MTT assay result against MCF-7 showed IC_{50} value of 68.59ppm. Based on preliminary *in-silico* studies inhibited Methionyl-tRNA Synthetase, 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one was synthesized and tested *in-vitro* against MCF-7. Albeit the compound does not possess better docking score than native ligand, it is still argued that benzoxazine ring can be considered as a potential anticancer agent, as showed by MTT assay result which indicated moderate cytotoxicity.

Keywords: Anticancer, benzoxazinone, elucidation, molecular docking, MTT assay.

INTRODUCTION

Cancer is one of the most fatal disease worldwide. It is caused by abnormal and uncontrolled growth of cells (American Cancer Society, 2019). Based on WHO data, breast cancer is one of the most prevalent types which occurs in 2.1 million women annually (Ferley *et al*., 2019; Kesuma *et al*., 2018). There are numerous mechanisms behind this disease, one of which is over expression of human methionyl-tRNA synthetase (MRS). This enzyme belongs to aminoacyl-tRNA synthetase group which acts as a coupling agent between tRNA with the appropriate amino acid. The amino acid-tRNA cognate is then utilized to build peptide. Over expression of methionyl-tRNA synthetase has been found in several different type of cancer (Kim *et al*., 2011; Bharathkumar *et al*., 2015) Therefore, MRS can become one of therapeutic target to develop novel selective anticancer agents. Studies showed that benzoxazine-a heterocyclic compound-possesses selective activity in inhibiting human MRS. It has also been found that this class of compound to be cytotoxic in breast cancer cell MCF-7. Recently, 2-phenyl-4*H*-benzo[d][1,3]oxazin-4-one derivatives possesses moderate cytotoxicity against several cancer cell line (El-Azab *et al*., 2010; Kesuma *et al*., 2020). In this study, several analogues of dihalo-2-phenyl-4H-benzo[d][1,3]oxazin-4-one were predicted in silico using molecular docking against human MRS. The best predicted compound was then synthesized and underwent MTT assay against breast cancer cell MCF-7 to verify its activity *in vitro*. Comprehensive chemical structure characterization was also performed to verify the correctness of synthesized compound.

MATERIALS AND METHODS

Molecular docking study

Molecular docking was performed using MVD (Molegro® Virtual Docker version 5.5) (Thomsen & Christensen, 2006). The compounds were built initially in 2D and then optimized geometrically into 3D using MMFF94 (Halgren, 1996). These compounds were then docked into the active site of human methionyl-tRNA synthetase (MRS) (PDB ID: 1PG2)(Bharathkumar *et al*., 2015; Crepin *et al*., 2003). Redocking of native ligand (2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydro-furan-3,4-diol) was performed in order to ensure the validity of molecular docking method. The method was considered valid when RMSD value obtained less than 2.0 A. After redocking process, all benzo[d][1,3]oxazin-4-

*Corresponding author: e-mail: galih_satrio_putra@yahoo.com; galih.satrio.fmipa@um.ac.id

one derivatives were docked into active site of MRS enzyme. MolDock score was utilized as ligand-protein scoring function (Thomsen & Christensen, 2006). In addition, re-ranking was performed based on Lennard-Jones steric energy (Thomsen & Christensen, 2006). The compound which yielded the lowest docking score was chosen to be synthesized and evaluated of its anticancer activity through bioassay against MCF-7 cell.

Synthesis and structure elucidation

Chemicals used for synthesis including: Anthranilic acid (Merck); 3,4-dichlorobenzoyl chloride (Sigma Aldrich); Pyridine (Merck); Distilled water; Sodium Bicarbonate (Merck); Ethanol (Merck); n-Hexane (Merck); Ethyl acetate (Merck); Chloroform (Merck); Acetone (Merck).

Characterization of target compound was performed using various spectroscopic method. NMR spectra measurements were conducted using JEOL ECS-400 spectrometer, MS spectra were measured in QSTAR XL NanoSpray™ using Electrospray ionization (ESI) mode. FT-IR spectra was obtained in Jasco FT-IR 5300, Ultraviolet spectra was recorded using Shimadzu UV-Vis Spectrophotometer 1800. In addition, melting point of the compound was determined using Fisher-John Electrothermal Mel-Temp.

Anthranilic acid 1.37g (10mmol) was dissolved in pyridine, then added slowly with 3,4-dichlorobenzoyl chloride (12mmol). The reaction was performed in 0ºC for 15 minutes. Afterwards, the mixture was put in the room temperature up to one hour. The whole process was taken place under constant stirring. In order to evaluate the completion of reaction, TLC was employed using silica gel 60 GF254 (Merck) and equimolar mixture of n-hexane-ethyl acetate as eluent. Afterwards, the mixture was added by 10% solution of sodium bicarbonate followed by distilled water. The solid phase was obtained after vacuum-filtration, then recrystallized in ethanol-acetone (5:1) solution.

Anticancer activity test

The anticancer activity study was performed using MTT assay approach. The MCF-7 cells were seeded into 96-well plates and incubated for 24 hours in 5% CO_2. There were three groups prepared consisted of positive, negative and control group. Positive group contains the mixture of cancer cell with the synthesized compound in several different concentration (7.00 until 250.00µg/mL, each concentration was replicated five times). Meanwhile, negative and control group only contain cancer cell and medium, respectively. In the end of incubation period, each well was added with 100µL of 0.5mg/mL MTT, followed by another 3 hours of incubation time. MTT reagent will be converted by live cells into formazan which yields dark blue color. This reaction was quenched by adding 100µL of 10% SDS in 0.01 N HCI into each well. The micro plates were then wrapped in paper and re-incubated at 37ºC for 24 hours. Elisa reader was utilized to identify the absorption at λ =595nm. Ultimately, percentage of cell viability was calculated to determine IC_{50} value of the compound (Riss *et al*., 2016).

$$\% \text{ cell viability} = \frac{\text{Abs.Positive controls - Abs Media controls}}{\text{Abs.Negative controls - Abs Media controls}} \times 100$$

RESULTS

Molecular docking study

Synthesis and structure elucidation

This study has successfully synthesized 2-(3,4-dichlorophenyl)-4*H*-benzo[d][1,3]oxazin-4-one with good yield. Furthermore, spectroscopic characterizations (fig. 3) have concluded the validity of the synthesized compound.



Fig. 1: Comparison of its native ligand (green) with the doking result simulation (yellow) by Molegro Virtual Docker (MVD) software Ver.5.5. The RMSD is 0.84A

Anticancer activity study

The result of MTT assay shown in table 3. The calculation IC_{50} value of 2-(3,4-dichlorophenyl)-4*H*-benzo[d][1,3]oxazin-4-one is 70.74±3.95µg/mL equivalent to 2.35 mM.

DISCUSSION

In-silico study

Molecular docking study has been long employed as a tool to predict ligand binding affinity towards receptor. Here, this method was applied as a preliminary study to predict the most potent compound among several 2-dihalophenylbenzoxazinone analogues against MRS. MolDock score was implemented as a scoring function to assess the predicted activity of compounds. This scoring function is based on guided differential evolutionary algorithm, where it employs PLP function with an improvement in terms of hydrogen bond and charge schemes (Thomsen & Christensen, 2006; de Azevedo, 2010). Furthermore, post-process re-ranking was introduced based on weighted approximation of Lennard-Jones 12-6 potential to better characterize steric interaction. The result showed that native ligand possess docking score of -93.48±0.07 kcal/mol with hydrogen bond interaction predicted with Glu27; His28; Gly294;

Table 1: Molecular Docking result of compounds and its native ligand on active site human methionyl-tRNA synthetase

Compound	Rerank Score (Kcal/mol)	Doked Pose	Hydrogen Bond	Amino acids residues	Steric Interaction	Amino acids residues
 (Native ligand)	-93.48 ±0.07	√	5	Glu 27 His 28 Gly 294 Asp 296 Val 326	2	His 21 Glu 27
 Lead Compound	-74.50 ±0.03	√	-	-	3	His 24 Gly 27 His 323
 1	-74.74 ±0.05	√	-	-	4	His 24 Gly 27 His 323 Val 326
 2	-68.39 ±0.02	√	-	-	4	Ala 12 His 24 His 323 Val 326
 3	-69.05±0.06	√	-	-	4	Ala 12 Leu 13 His 323 Val 326
 4	-67.69±0.05	√	-	-	4	Ala 12 Leu 13 His 24 Val 326

Table 2: Summary spectra data 1D NMR (^{1}H and ^{13}C-NMR) and 2D NMR (HMQC, HMBC, COSY) and MS, FTIR and UV of 2-(3,4-dichlorophenyl)-4*H*-benzo[1,3]oxazin-4-one



Kinds of Spectra	Characteristics
^{1}H-NMR Spectrum (400 MHz, DMSO-d_6)	δ 8.27 (d, *J*=2.0 Hz, 1H), 8.14 (dd, *J*=7.9, 1.2 Hz, 1H), 8.10 (dd, *J* = 8.5, 1.8 Hz, 1H), 7.97-7.91 (m, 1H), 7.85 (d, *J*=8.5 Hz, 1H), 7.72 (d, *J*=8.0 Hz, 1H), 7.63 (t, *J*=7.6 Hz, 1H).There are 7 atoms of Hydrogen
^{13}C-NMR Spectrum (100 MHz, DMSO-d_6)	δ 159.0, 155.0, 146.4, 137.6, 136.0, 132.5, 132.0, 131.3, 129.8, 129.6, 128.7, 128.3, 127.6, 117.6. There are 14 atoms of Carbon.
COSY Spectrum (DMSO-d_6)	(8.14; 7.63); (8.10; 7.85); (7.95; 7.72) and (7.95; 7.63); (7.85; 8.10); (7.72; 7.75); (7.63; 8.14) and (7.63; 7.95)
HMQC Spectrum (DMSO-d_6)	(8.27;129.8); (8.14;128.3); (8.10;128.7); (7.95;137.6); (7.85;132.0); (7.72;127.6); (7.63;129.6)
HMBC Spectrum (DMSO-d_6)	(8.27; 136.0; 132.5); (8.14; 159.0; 146.4; 117.6); (8.10; 131.3);(7.95;146.4); (7.85; 155.0; 132.5; 131.3); (7.72; 129.6; 117.6); (7.63; 137.6; 117.6)
Mass Spectrum *ESI/MS* m/z *values (Rel. abundance)*	$C_{14}H_8O_2NCl_2$. [M^{+}]+= 292 (100%); [M^{+2}]+=295 (65%); [M^{+4}]= 296 (10%).fragments m/z :217; 173; 175; 177,
FT-IR Spectrum (KBr, v max, cm^{-1})	1760 (C=O lactone); 1621 and 1474 (C=C aromatic); 3090 (=C-H aromatic); 1620 (C=N); 1324 (C-N); C-Cl (770) and C-O-C (1255)
Ultraviolet Spectrum	λ max (nm) 288; 300, in ethanol 70 % solution with 50.0 ppm concentration

Table 3: Anticancer activity of 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one against Human Breast Cancer Cell Line MCF-7.

Concentrations (µg/mL)	Absorbance	Cell Viabilities (%)	IC_{50} (ppm)
7.81	0.504±0.013	68.54±1.87	70.74±3.95
15.25	0.469±0.005	62.66±0.77	
31.25	0.465±0.008	61,97±1.44	
62.50	0.463±0.021	61,52±3.66	
125.00	0.346±0.005	41,62±0.79	
250.00	0.289±0.001	31,76±1.68	
Negative Control	0.688±0.006	100	

Absorbance media control= 0.103±0.001

Tabel 4: Cross-peaks in heteronuclear multiple-bond correlation (HMQC) and Heteronuclear Multiple Bond Correlation (HMBC) spectra of 2-(3,4-dichlorophenyl)-4H-benzo[1,3]oxazin-4-one



No	HMQC		Cosy	HMBC
	H-NMR	C-NMR		
1	8.14 (dd, *J* = 7.9, 1.2 Hz, 1H)	128.3	H2	C5;C6;C7
2	7.63 (t, *J* = 7.6 Hz, 1H)	129.6	H1;H3	C4;C6
3	7.97 – 7.91 (m, 1H)	137.6	H2;H4	C5;C6;C7
4	7.72 (d, *J* = 8.0 Hz, 1H)	127.6	H3	C2;C6
5	-	146.4	-	-
6	-	117.6	-	-
7	-	159.0	-	-
8	-	155.0	-	-
9	-	131.3	-	-
10	7.85 (d, *J* = 8.5 Hz, 1H)	132.0	H11	C8;C9;C13
11	8.10 (dd, *J* = 8.5, 1.8 Hz, 1H)	128.7	H10	C9
12	-	136.0	-	-
13	-	132.5	-	-
14	8.27 (d, *J* = 2.0 Hz, 1H)	129.8	-	C10;C12

Asp296; Val 326 and steric interaction with His21 and Glu27. On the other hand, all of designed compound does not show any interaction but steric interaction with several residues (His24; Gly27; His323; Val326; Ala12; Leu13) in the active site.

This indicates the addition of halo substituents only create steric interaction with receptor, which manifested in higher docking scores than native ligand. Among several designed analogues, 3,4-dichloro compound possess the best docking score of -74.74±0.05kcal/mol. Therefore, it is chosen to be evaluated further *in-vitro* to verify its potency as anticancer agent.

Synthesis and structure elucidation

Compound 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3] oxazin-4-one was obtained by reacting anthranilic acid (1) (10mmol) with 3,4-dichlorobenzoyl chloride (2) (1.2 mmol) in pyridine (fig. 4). The mixture was constantly stirred at 0°C for 1 hour to yield 88% ± 2% (n=6).

The reaction was taken place in two steps. Initially, amine group of (1) as nucleophile attacks carbonyl center of 2-(3,4-dichlorophenyl)-4*H*-benzo[d][1,3]oxazin-4-one via SN-acyl. Pyridine aided in the deprotonation process of the hydrogen atom of amine group. This yielded to a tetrahedral intermediate product which continue to form 3' (fig. 5). Subsequently, pyridine acted as deprotonating agent for carboxylic moiety of 3' to yield carboxylate anion which then proceeded to attack the resulting amide group intramolecularly. This cyclization resulted to a benzoxazine ring (3) (Putra *et al*., 2017; Noolvi *et al*., 2011; Noolvi *et al*., 2013) (fig. 6).

Determination of compound 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one was confirmed by 1H-NMR, 13C-NMR, various 2D-NMR analysis (COSY, HMQC, HMBC), MS and IR spectral data. In addition, UV spectral data was also provided to determine the maximum wavelengths of the compound (288 and 300 nm) where it is possible to measure the linearity of concentration and absorbance according to Lambert-Beer equation.



Fig. 2: The Interaction between native ligand, lead compoud and compounds 1-4 into active site human methionyl-tRNA synthetase

The ^{1}H-NMR spectrum of compound 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one showed peaks around δ 6.5-8 ppm, indicating the existence of 7 protons of aromatic ring (fig. 3).

Meanwhile, ^{13}C-NMR similarly showed the presence of two aromatic rings (fig. 3). Furthermore, the presence of carbonyl fragment at δ 159 ppm and imine fragment at δ 155 ppm pointed the formation of benzoxazinone ring.
2D NMR analysis further confirmed the correlation of proton and carbon atom of the structure. Based on HMQC analysis, 7 protons of compound 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one have been assigned to their counterpart carbon atoms (Benzoxazinone ring: 8.14 ppm-128.3 ppm; 7.63 ppm-129.6 ppm; 7.95 ppm-137.6 ppm; 7.71 ppm-127.6 ppm, Dichlorophenyl ring: 8.27 ppm-129.8 ppm; 7.85 ppm-132.0 ppm; 8.10 ppm-128.7 ppm) shown in fig. 3.

Furthermore, HMBC spectral data showed long range interaction between H atom at position C-10 with C-8 (N=C-O) indicating the creation of C-C bond between dichlorophenyl and benzoxazinone ring (fig. 3). Correlation spectroscopy (COSY) shown in fig. 3, the result pointed that all of the hydrogen position is in accordance with the proposed structure (table 2).

Mass spectroscopy confirmed the molecular weight of 291.99 ([M+H]+), with mass deviation of 0.13 (<5mmu) from theoretical molecular weight. The fragmentation pattern confirmed the molecular formula of $C_{14}H_8O_2NCl_2$. The presence of chlorine atom was confirmed by the molecular peaks with m/z = 292 (M; 100%); m/z = 294 (M+2; 65%); m/z = 296 (M+4; 10%) shown in fig. 3.

The relative abundance pattern of 10:6:1 indicates that the compound possesses two chlorine atoms (Pavia *et al*., 2009). Furthermore, the formation of N=C-$C_5H_3Cl_2$ fragment with m/z value of 173 and 175 confirmed the formation of target compound (fig. 3). Ultimately, infrared spectral data showed the formation of benzoxazinone ring manifested in absorption band at 1621 cm-1 (-C=N bond) and 1760 cm-1 (C=O lactone bond) (Putra *et al*.,2017; Pavia *et al*.,2009) shown in fig. 3.

Anticancer activity study

Based on the anti-cancer activity result, 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one possess anticancer activity againts Human Breast Cancer cell line MCF-7, with IC_{50} value of 70.74±3.95µg/mL. This result is classified as low cytotoxicity activity based on MTT assay criteria (50-100µg/mL) (Batista el al., 2009; Cos *et al*., 2006; Weerapreeyakul., 2012; Indrayanto *et al*., 2020) Based on previous research (Kesuma *et al*., 2020), it is known that benzoxazinone scaffold without any substituent has IC_{50} value of 65.43±2.7µg/mL against A549 cell line (fig. 7).



Fig. 3: A. ^{1}H-NMR (400 MHz) spectrum in DMSO-d6. B. ^{13}C-NMR (400 MHz) spectrum in DMSO-d6. C. HMQC spectrum. D. HMBC Spectrum. E. COSY spectrum. F. MS spectrum (ESI Method). G.FT-IR spectrum in KBr pellet. H. Ultraviolet Spectrum in ethanol 70% (50.0 ppm consentration)



Fig. 7: MCF-7 cells before administration of a test compound: living cells condition (A and C) and MCF-7 cells after administration of a test compound with a dose of 250 µg/mL (B) and of 125 µg/mL (D): the presence of dead cells after administration of a test compound (B and D).

This finding indicates that addition of halo- substituent yields no significant impact in improving anticancer activity of benzoxazinone compound. This is also in accordance with molecular docking result, in which there is no difference in docking score between 2-phenylbenzoxazinone with its substituted counterpart. Generally, it is evident that 1,3-benzoxaxine scaffold.

Possess anticancer activity and study has shown several analogues can be considered as potent as anticancer agent with good cytotoxicity (El-Azab *et al*., 2010). Therefore, it is necessary to re-examine which substitution pattern is the most important in order to improve the activity of this scaffold.



Fig. 4: Synthesis of 2-(3,4-dichlorophenyl)-4*H*-benzo[d][1,3]oxazin-4-one from anthranilic acid (1) and 3,4-dichlorobenzoylchloride (2)



Fig. 5: Reaction mechanism between anthranilic acid (1) and 3,4-dichlorobenzoyl chloride to form 2-(3,4-dichlorobenzamido)benzoic acid (3')



Fig. 6 : Reaction mechanism of the formation of 2-(3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one (3)

CONCLUSION

2-(3,4-dichlorophenyl)-4*H*-benzo[d][1,3]oxazin-4-one has been synthesized with a very good yield (88%±2%) and has been characterized with various spectroscopic analysis (1D NMR (H and C-NMR); 2D NMR (COSY, HMQC, HMBC), MS, FTIR). Based on in vitro assay, this compound is classified as low cytotoxic against MCF-7 cell line with IC_{50} value of 70.74±3.95µg/mL. The result was in accordance with molecular docking outcome, which indicated no significant difference between the compound and unsubstituted 2-phenylbenzoxazinone.

ACKNOWLEDGEMENT

The authors are thankful to ITD Airlangga for collecting all spectra data especially 1D and 2D NMR and Hiroshima University (Katsuyoshi Matsunami) for the help in MS data acquisition

REFERENCES

American Cancer Society (2019). Breast Cancer Facts & Figures 2019-2020. American Cancer Society, Inc. Atlanta.

Batista Ronan, Júnior AJS and Braga de Oliveira A (2009). Plant derived antimalarial agents: new leads and efficient phytomedicines. Part II. Non Alkaloidal Natural Products, *Molecules*, **14**(8): 3037 3072.

Bharathkumar H, Mohan CD, Rangappa S, Kang T, Keerthy HK, Fuchs JE, Kwon NH, Bender A, Kim S, Basappa Rangappa KS (2015). Screening of quinoline, 1,3-benzoxazine and 1,3-oxazine-based small molecules against isolated methionyl-tRNA synthetase and A549 and HCT116 cancer cells including an *in silico* binding mode analysis. *Org. Biomol. Chem.,* **13**(36): 9381-9387.

Cos Paul, Vlietinck AJ, Berghe DV and Maesa L (2006). Anti-infective potential of natural products: How to develop a stronger *in vitro* 'proof-of-concept'. *J. Ethnopharmacol*, **106**(3): 290-302.

Crepin T, Schmitt E, Mechulam Y, Sampson PB, Vaughan MD, Honek JF and Blanquet S (2003). Use of analogues of methionine and methionyl adenylate to sample conformational changes during catalysis in Escherichia coli methionyl-tRNA synthetase. *J. Mol. Biol,* **332**(1): 59-72.

De Azevedo Jr WFJ (2010). MolDock applied to structure-based virtual screening. *Curr. Drug Targets,* **11**(3): 327-334.

El-Azab AS, Al-Omar MA, Abdel-Aziz AAM, Abdel-Aziz NI, El-Sayed MAA, Aleisa AM, Sayed-Ahmed MM and Abdel-Hamide SG (2010). Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study. *Eur. J. Med. Chem.* **45**(9): 4188-4198.

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int. J. Cancer,* **144**(8): 1941-1953.

G Indrayanto, GS Putra and F Suhud (2021). Chapter Six - Validation of *in-vitro* bioassay methods: Application in herbal drug research, Editor(s): Abdulrahman A. Al-Majed, Profiles of Drug Substances, Excipients and Related Methodology, Academic Press, **46**(1): 273-307.

Halgren TA (1996). Merck Molecular Force Field. Basis, form, scope, parametrization, and performance of MMFF94. *J. Comput. Chem.,* **17**(5-6): 490-519.

Kesuma D, Putra GS, Yuniarta TA, Sulistyowaty MI and Siswandono Budiati T (2020). Synthesis of 2-phenyl-4H-benzo[d][1,3]oxazin-4-one and its biological activity against A549 cancer cell line through Methionyl-tRNA synthetase inhibition approach on *in-silico* studies. *Int. J. Pharm. Res.* pp.564-571

Kesuma D, Siswandono Purwanto BT and Rudyanto M (2018). Synthesis of N-(phenylcarbamothioyl)-benzamide derivatives and their cytotoxic activity against MCF-7 cells. *J. Chin. Pharm. Sci.,* **27**(10): 696-702.

Kim, S., You, S., Hwang, D. (2011). Aminoacyl -tRNA synthetases and tumorigenesis: More than housekeeping. *Nat. Rev. Cancer,* **11**(1): 708-718.

Noolvi M and Patel H (2013). Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted Quinazoline derivatives and targeting EGFR-tyrosine kinase by rational approach. *Arab. J. Chem.,* **6**(1): 35-48.

Noolvi M, Patel H, Bhardwaj V and Chauhan A (2011). Synthesis and *in vitro* antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent. *Eur. J. Med. Chem.* **46**(6): 2327-2346

Pavia Donald L, Lampman GM, Kriz GS, Vyvyan JR Indroduction to Spectrscopy. Ed. 4th. (2009). US: Brooks/Cole, Cengage Learning, pp.440-447.

Putra GS, Widiyana AP, Muchlashi LA, Sulistyowaty MI, Ekowati J, Budiati T (2017). The influence of ratio pyridine and triethylamine catalysts on synthesis 2-phenyl-benzo[D] [1,3]oxazine-4-on derivatives. *J. Chem. Pharm.,* **9**(8): 73-80.

Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ and Minor L Cell Viability Assays (2016). *In*: Sittampalam GS, Grossman A, Brimacombe K, *et al*., editors. Assay Guidance Manual Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences, pp.1-25

Thomsen R and Christensen MH (2006). MolDock: A new technique for high-accuracy molecular docking. *J. Med. Chem.*. **49**(11): 3315-3321.

Weerapreeyakul Natthida, Nonpunya A, Barusrux S, Thitimetharoch T and Sripanidkulchai B (2012). Evaluation of the anticancer potential of six herbs against a hepatoma cell line. *Chin. Med.,* **7** (1): 15.

Pakistan Journal of Pharmaceutical Sciences

Faculty of Pharmacy, University of Karachi
Karachi-75270, Pakistan

Patron

- Nasira Khatoon (University Of Karachi, Pakistan)

Editor-in-chief

- Faiyaz HM Vaid (University Of Karachi, Pakistan)

Associate Editor

- Iqbal Azhar (University Of Karachi, Karachi, Pakistan)

Advisory Board

- Abdel-Aziz El-Basyouni M. Wahbi (University Of Alexandria, Egypt)
- Anwarul Hassan Gilani (Pakistan Council For Science And Technology, Islamabad, Pakistan)
- Biswadeep Das (Chennai Med. College Hosp. & Res. Center, India)
- Eduardo José Caldeira (Faculty Of Medicine Of Jundiaí, São Paulo, Brazil)
- Fawkeya Abd Allah Abbas (Zagazig University, Zagazig, Egypt)
- Fouzia Hassan (University Of Karachi, Pakistan)
- Ghazala H. Rizwani (Hamdard University, Karachi, Pakistan)
- Hitoshi Tanaka (Meijo University, Tempaku-ku, Nagoya, Japan)
- Ileana Cornelia Farcasanu (Bucharest University, Bucharest, Romania)
- Iqbal Ahmad (Baqai Medical University, Karachi, Pakistan)
- Jamshed Ali Kazmi (Jinnah Medical & Dental College, Karachi, Pakistan)
- Joachim W Herzig (Johannes Gutenberg University, Grenzach-Wyhlen, Germany)
- Judit Hohmann (Universitiy Of Szeged, Szeged, Hungary)
- Khursheed Hasan Hashmi (LNH & Medical College, Karachi, Pakistan)
- M Shaiq Ali (University Of Karachi, Karachi, Pakistan)
- M. Izham Mohamed Ibrahim (College Of Pharmacy, Qatar University, Doha, Qatar)
- Maged Saad Abdel-Kader (University Of Alexandria, Egypt)
- Manoranjan Adak (Nat. Medical College & Teaching Hospital, Birgunj, Nepal)
- Mansoor Ahmad (University Of Karachi, Karachi, Pakistan)
- Mehdi Mahmoodi Salehabad (Faculty Of Medicine, Rafsanjan, Iran)
- Meherzia MOKNI (Department Of Biology, Faculty Of Sciences Of Tunis, Tunisia)
- Michel Bourin (Nantes, France)
- Mohammad Amjad Kamal (King Abdulaziz University, Jeddah, Saudi Arabia)
- Mohammad Jamshed Ahmad Siddiqui (International Islamic University Malaysia (IIUM), Malaysia)
- Muhammad Harris Shoaib (University Of Karachi, Pakistan)
- Naoharu Watanabe (Shizuoka University, Shizuoka, Japan)
- Nousheen Mushtaq (University Of Karachi, Karachi, Pakistan)
- Rafeeq Alam Khan (Ziauddin University, Karachi, Pakistan)
- Rahila Ikram (Barrett Hodgson University, Karachi, Pakistan)
- S. Waseemuddin Ahmed (Benazir Bhutto Shaheed University, Karachi, Pakistan)
- Shah Ali-UL-Qader (University Of Karachi, Karachi, Pakistan)
- Shamim Akhter (University Of Karachi, Pakistan)
- Tom Boudewijn Vree (Nijmegen, The Netherlands)
- Tong-Shui Zhou (Fudan University, Shanghai, China)
- Zafar Alam Mahmood (Colorcon Limited, England)

ISSN 1011-601X
JCR Impact Factor (2020) 0.684
JCR 5-Years Impact Factor 0.704
IndexCopernicus 16.06

Most Cited Articles

Search

Enter text to search

Search Article

Editor-in-Chief

Prof. Dr. Faiyaz HM Vaid
2020 - todate

Ex-Editors-in-Chief

Associated Journals

Following is the list of all articles published in the current issue. Click on the article to view it.

If you wish to see articles in the previous issues Click Here.

Volume : 35, Issue : 5, Sep 2022

Pakistan Journal of Pharmaceutical Sciences

COUNTRY

Pakistan

Universities and research institutions in Pakistan

SUBJECT AREA AND CATEGORY

Pharmacology, Toxicology and Pharmaceutics

Pharmaceutical Science

PUBLISHER

Pakistan Journal of Pharmaceutical Sciences

H-INDEX

42

PUBLICATION TYPE

Journals

ISSN

1011601X

COVERAGE

1995, 2005-2021

INFORMATION

Homepage

How to publish in this journal

pjps@uok.edu.pk

SCOPE

Pakistan Journal of Pharmaceutical Sciences (PJPS) is a peer reviewed multi-disciplinary pharmaceutical sciences journal. The PJPS had its origin in 1988 from the Faculty of Pharmacy, University of Karachi as a biannual journal, frequency converted as quarterly in 2005, and now PJPS is being published as bi-monthly from January 2013. PJPS covers Biological, Pharmaceutical and Medicinal Research (Drug Delivery, Pharmacy Management, Molecular Biology, Biochemical, Pharmacology, Pharmacokinetics, Phytochemical, Bio-analytical, Therapeutics, Biotechnology and research on nano particles.

Quartiles

FIND SIMILAR JOURNALS

1	2	3	4
Pharmacologyonline	**Oriental Pharmacy and Experimental Medicine**	**Pharmacognosy Magazine**	**International Journal of Green Pharmacy**
ITA	USA	IND	IND
69%	65%	64%	62%















← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scima
```

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization**

Source details

Pakistan Journal of Pharmaceutical Sciences

Scopus coverage years: 1995, from 2005 to Present
Publisher: University of Karachi
ISSN: 1011-601X
Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science
Source type: Journal

View all documents > | Set document alert | Save to source list

CiteScore 2021
1.2

SJR 2021
0.218

SNIP 2021
0.350

CiteScore | CiteScore rank & trend | Scopus content coverage

CiteScore 2021

$$1.2 = \frac{1{,}849 \text{ Citations } 2018 - 2021}{1{,}509 \text{ Documents } 2018 - 2021}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022

$$1.3 = \frac{1{,}581 \text{ Citations to date}}{1{,}211 \text{ Documents to date}}$$

Last updated on 05 September, 2022 • Updated monthly

CiteScore rank 2021

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics └ Pharmaceutical Science	#106/171	38th

View CiteScore methodology > | CiteScore FAQ > | Add CiteScore to your site

About Scopus

What is Scopus

Content coverage

Scopus blog

Scopus API

Privacy matters

Language

日本語版を表示する

查看简体中文版本

查看繁體中文版本

Просмотр версии на русском языке

Customer Service

Help

Tutorials

Contact us